Sign In
Buy PROK
$1.73
-0.170 (-8.95%)
At Close: Jun 03, 2026
ProKidney Appoints Kenneth Locke as Chief Technical Officer
08:00am, Tuesday, 02'nd Jun 2026
Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potenti
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
01:55pm, Friday, 15'th May 2026
ProKidney Corp. (PROK) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.
ProKidney Reports First Quarter 2026 Financial Results and Business Highlights
11:45am, Friday, 15'th May 2026
WINSTON-SALEM, N.C., May 15, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney
Head-To-Head Contrast: ProKidney (NASDAQ:PROK) & Phio Pharmaceuticals (NASDAQ:PHIO)
02:19am, Friday, 27'th Mar 2026
Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) and ProKidney (NASDAQ: PROK - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two b
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
04:01pm, Wednesday, 25'th Mar 2026
WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidne
ProKidney Corp. (NASDAQ:PROK) Given Consensus Recommendation of “Moderate Buy” by Brokerages
02:14am, Sunday, 22'nd Mar 2026
Shares of ProKidney Corp. (NASDAQ: PROK - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight ratings firms that are presently covering the firm, MarketBeat reports. Two i
ProKidney (PROK) Projected to Post Earnings on Monday
02:05am, Monday, 09'th Mar 2026
ProKidney (NASDAQ: PROK - Get Free Report) will likely be releasing its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect the company to announce earnings of ($0.16) per s
ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably
04:40am, Saturday, 31'st Jan 2026
PROK's main value driver is Rilparencel, which is now in a pivotal trial called PROACT 1. The FDA also accepted using eGFR slope analysis for evaluating its potential accelerated approval. PROK believ
ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
01:36pm, Wednesday, 14'th Jan 2026
ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
07:30am, Tuesday, 06'th Jan 2026
WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidne
ProKidney Corp. (NASDAQ:PROK) Receives Average Rating of “Hold” from Analysts
03:32am, Monday, 17'th Nov 2025
Shares of ProKidney Corp. (NASDAQ: PROK - Get Free Report) have been given a consensus recommendation of "Hold" by the six research firms that are currently covering the company, MarketBeat reports. T
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
04:15pm, Monday, 10'th Nov 2025
WINSTON-SALEM, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidne
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
11:00am, Thursday, 06'th Nov 2025
WINSTON-SALEM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on CKD, today pr
Head-To-Head Review: Tonix Pharmaceuticals (NASDAQ:TNXP) versus ProKidney (NASDAQ:PROK)
02:46am, Wednesday, 05'th Nov 2025
Tonix Pharmaceuticals (NASDAQ: TNXP - Get Free Report) and ProKidney (NASDAQ: PROK - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two bu
WINSTON-SALEM, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chro
